XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)
$ / shares in Thousands
Mar. 31, 2023
Dec. 31, 2022
Unrestricted cash and cash equivalents $ 389,835,000 $ 384,984,000
Restricted cash and cash equivalents 44,677,000 48,208,000
Loans, interest and fees receivable, at fair value 1,795,589,000 1,817,976,000
Notes payable, at face value $ 1,614,575,000 $ 1,653,306,000
Common stock, par value (in dollars per share) $ 0 $ 0
Common stock, authorized (in shares) 150,000,000 150,000,000
Common stock, issued (in shares) 14,528,546 14,453,415
Common stock, outstanding (in shares) 14,528,546 14,453,415
Series A Preferred Stock [Member]    
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 400,000 400,000
Preferred stock, shares outstanding (in shares) 400,000 400,000
Preferred stock, liquidation preference $ 40,000 $ 40,000
Series B Preferred Stock [Member]    
Preferred stock, no par value (in dollars per share) $ 0 $ 0
Preferred stock, shares issued (in shares) 3,254,161 3,204,640
Preferred stock, shares outstanding (in shares) 3,254,161 3,204,640
Preferred stock, liquidation preference $ 81,400,000 $ 81,400,000
Variable Interest Entity, Primary Beneficiary [Member]    
Unrestricted cash and cash equivalents 186,800,000 202,200,000
Restricted cash and cash equivalents 27,900,000 27,600,000
Loans, interest and fees receivable, at fair value 1,735,300,000 1,735,900,000
Notes payable, at face value $ 1,543,700,000 $ 1,586,000,000